AU6407899A - Compositions and methods for wt1 specific immunotherapy - Google Patents

Compositions and methods for wt1 specific immunotherapy Download PDF

Info

Publication number
AU6407899A
AU6407899A AU64078/99A AU6407899A AU6407899A AU 6407899 A AU6407899 A AU 6407899A AU 64078/99 A AU64078/99 A AU 64078/99A AU 6407899 A AU6407899 A AU 6407899A AU 6407899 A AU6407899 A AU 6407899A
Authority
AU
Australia
Prior art keywords
seq
polypeptide
patient
cells
wti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU64078/99A
Other languages
English (en)
Inventor
Martin Cheever
Alexander Gaiger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/164,223 external-priority patent/US7063854B1/en
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of AU6407899A publication Critical patent/AU6407899A/en
Priority to AU2003257511A priority Critical patent/AU2003257511B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU64078/99A 1998-09-30 1999-09-30 Compositions and methods for wt1 specific immunotherapy Abandoned AU6407899A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003257511A AU2003257511B2 (en) 1998-09-30 2003-10-23 Compositions and methods for WT1 specific immunotherapy

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09164223 1998-09-30
US09/164,223 US7063854B1 (en) 1998-09-30 1998-09-30 Composition and methods for WTI specific immunotherapy
US27648499A 1999-03-25 1999-03-25
US09276484 1999-03-25
PCT/US1999/022819 WO2000018795A2 (en) 1998-09-30 1999-09-30 Compositions and methods for wt1 specific immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2003257511A Division AU2003257511B2 (en) 1998-09-30 2003-10-23 Compositions and methods for WT1 specific immunotherapy

Publications (1)

Publication Number Publication Date
AU6407899A true AU6407899A (en) 2000-04-17

Family

ID=26860363

Family Applications (1)

Application Number Title Priority Date Filing Date
AU64078/99A Abandoned AU6407899A (en) 1998-09-30 1999-09-30 Compositions and methods for wt1 specific immunotherapy

Country Status (25)

Country Link
EP (1) EP1117687B1 (https=)
JP (3) JP4243792B2 (https=)
KR (1) KR100752065B1 (https=)
CN (1) CN100486995C (https=)
AR (1) AR021849A1 (https=)
AT (1) ATE399179T1 (https=)
AU (1) AU6407899A (https=)
BR (1) BR9914116A (https=)
CA (1) CA2349442C (https=)
CZ (1) CZ20011144A3 (https=)
DE (1) DE69938970D1 (https=)
ES (1) ES2310052T3 (https=)
HK (1) HK1039782B (https=)
HU (1) HUP0103598A3 (https=)
IL (2) IL142216A0 (https=)
MX (1) MXPA01003344A (https=)
MY (1) MY139226A (https=)
NO (1) NO325839B1 (https=)
NZ (1) NZ510600A (https=)
PL (1) PL201881B1 (https=)
RU (1) RU2237674C2 (https=)
SA (1) SA00200872B1 (https=)
TR (1) TR200101482T2 (https=)
TW (1) TWI285648B (https=)
WO (1) WO2000018795A2 (https=)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
AU4932199A (en) * 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) * 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
WO2001025273A2 (en) * 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
CA2401070A1 (en) * 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
JP4592641B2 (ja) * 2000-05-24 2010-12-01 治夫 杉山 Ｗｔ１関連疾患の検査方法
JP3846199B2 (ja) 2000-05-24 2006-11-15 治夫 杉山 Ｗｔ１関連疾患の検査方法
EP1371664B1 (en) * 2001-03-22 2008-01-09 International Institute of Cancer Immunology, Inc. Wti modified peptide
ATE494905T1 (de) * 2001-06-29 2011-01-15 Chugai Pharmaceutical Co Ltd Krebsimpfstoff mit einem krebs-antigen auf grundlage des produkts aus dem tumorunterdrückungsgen wt1 und einem kationischen liposom
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US20050002951A1 (en) * 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
JP5230891B2 (ja) * 2001-09-28 2013-07-10 株式会社癌免疫研究所 抗原特異的ｔ細胞の新規な誘導方法
WO2003106682A1 (ja) * 2002-06-12 2003-12-24 中外製薬株式会社 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
WO2004024175A1 (ja) * 2002-09-12 2004-03-25 Haruo Sugiyama 癌抗原ペプチド製剤
ES2331305T3 (es) * 2002-09-20 2009-12-29 International Institute Of Cancer Immunology, Inc. Peptidos de wt1 de tipo sustituido.
ES2332590T3 (es) * 2003-01-15 2010-02-09 International Institute Of Cancer Immunology, Inc. Dimero peptidico.
WO2005001117A1 (ja) * 2003-06-27 2005-01-06 Haruo Sugiyama Ｗｔ１ワクチン適応患者の選択方法
KR101213015B1 (ko) * 2003-11-05 2012-12-26 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ１ 로부터 유도된 ｈｌａ-ｄｒ 결합성 항원 펩티드
PT1731605E (pt) * 2004-03-31 2010-04-14 Int Inst Cancer Immunology Inc Péptidos antigénicos de cancro derivados de wt1
EP1657250A1 (en) * 2004-11-11 2006-05-17 Charité - Universitätsmedizin Berlin HLA-A *01-binding T-cell epitope of WT1
RU2286146C1 (ru) * 2005-04-12 2006-10-27 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ лечения церебральных метастазов генерализованной меланомы кожи
RU2301061C2 (ru) * 2005-04-28 2007-06-20 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ лечения генерализованной меланомы кожи
CA2631292C (en) 2005-11-30 2014-05-06 International Institute Of Cancer Immunology, Inc. Derivatised wt1 cancer antigen peptides and their use
AU2007218649B2 (en) 2006-02-22 2013-01-10 International Institute Of Cancer Immunology, Inc. HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same
KR101543622B1 (ko) * 2006-10-17 2015-08-11 온코세라피 사이언스 가부시키가이샤 Ｍｐｈｏｓｐｈ1 또는 ｄｅｐｄｃ1 폴리펩티드를 발현하는 암에 대한 펩티드 백신
EP2341142B8 (en) 2006-12-28 2015-01-14 International Institute of Cancer Immunology, Inc. HLA-A*1101-restricted WT1 peptide and pharmaceutical composition comprising same
BRPI0808084A2 (pt) 2007-02-27 2014-07-22 Int Inst Cancer Immunology Inc Método para ativação de células t auxiliadoras e composição para uso no método.
WO2008106551A2 (en) * 2007-02-28 2008-09-04 The Govt. Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Serv. Brachyury polypeptides and methods for use
KR101773690B1 (ko) 2007-03-05 2017-08-31 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
EP2216041A4 (en) * 2007-11-20 2012-10-24 Nec Corp METHOD OF INDUCING A CYTOTOXIC T-CELL, CYTOTOXIC T-CELL INDUCTOR AND PHARMACEUTICAL COMPOSITION, AND VACCINE WITH THE INDUCTOR
CA2940962C (en) * 2007-12-05 2018-07-24 International Institute Of Cancer Immunology, Inc. Cancer vaccine composition
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
CN110542754A (zh) * 2009-05-19 2019-12-06 迈阿密大学 用于体外抗原呈递、评估疫苗功效及生物制剂和药物的免疫毒性的组合物、试剂盒和方法
KR20140009168A (ko) 2010-10-05 2014-01-22 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 헬퍼 ｔ 세포의 활성화 방법
MX2013011363A (es) * 2011-04-01 2014-04-25 Sloan Kettering Inst Cancer Anticuerpos para peptidos citosolicos.
CA2839663A1 (en) 2011-06-28 2013-01-03 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific t cell
JP6163486B2 (ja) 2012-07-02 2017-07-12 大日本住友製薬株式会社 癌抗原ペプチド経皮剤
SG10201705028WA (en) 2012-12-17 2017-07-28 Otsuka Pharma Co Ltd Method for activating helper t cell
EP2974734B1 (en) 2013-03-12 2018-10-10 Sumitomo Dainippon Pharma Co., Ltd. Liquid aqueous composition
SG11201507883SA (en) 2013-03-29 2015-10-29 Sumitomo Dainippon Pharma Co Ltd Wt1-antigen peptide conjugate vaccine
WO2014157704A1 (ja) 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン
KR20160007579A (ko) 2013-05-13 2016-01-20 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 면역요법의 임상 효과의 예측법
CN106170297A (zh) * 2013-09-20 2016-11-30 纪念斯隆-凯特琳癌症中心 用于wt‑1‑阳性疾病的组合/辅助疗法
JP6005305B2 (ja) 2014-02-26 2016-10-12 テラ株式会社 Ｗｔ１抗原性ポリペプチド、及び該ポリペプチドを含む抗腫瘍剤
ES2805094T3 (es) * 2014-12-11 2021-02-10 Int Inst Cancer Immunology Inc Inmunoterapia WT1 para enfermedad angiogénica intraocular
JP6947720B2 (ja) * 2015-09-10 2021-10-13 メモリアル スローン ケタリング キャンサー センター Ｔ細胞療法による多発性骨髄腫及び形質細胞白血病の治療方法
SMT202200370T1 (it) * 2015-11-20 2022-11-18 Memorial Sloan Kettering Cancer Center Composizione per il trattamento del cancro
CN105254760B (zh) * 2015-11-21 2018-08-17 福州迈新生物技术开发有限公司 一株分泌抗wt1蛋白的单克隆抗体及其应用
US12383608B2 (en) 2016-11-30 2025-08-12 Sumitomo Pharma Co., Ltd. WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides
JPWO2018181648A1 (ja) 2017-03-30 2020-02-13 大日本住友製薬株式会社 Ｗｔ１癌抗原ペプチドおよびこれを含むペプチドコンジュゲート体
BR112019020959A2 (pt) * 2017-04-10 2020-05-05 Immatics Biotechnologies Gmbh peptídeos e combinações dos mesmos para uso na imunoterapia contra câncer
MX2020006119A (es) 2017-12-21 2020-08-24 Hoffmann La Roche Anticuerpos de union a hla-a2/wt1.
CN109758575B (zh) * 2018-02-14 2022-08-30 上海微球生物科技有限公司 充分多样的双亲性mhc ii结合多肽、免疫载体微球及其制备方法和应用
JP7162675B2 (ja) 2018-09-28 2022-10-28 住友ファーマ株式会社 注射用組成物
TWI875736B (zh) 2019-02-28 2025-03-11 日商住友製藥股份有限公司 選擇可期待用於治療或預防癌之醫藥組合物之效果之對象之方法
JP7153287B2 (ja) 2020-05-12 2022-10-14 住友ファーマ株式会社 癌を処置するための医薬組成物
WO2021231376A2 (en) * 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
CN111647066B (zh) * 2020-07-01 2020-12-18 维肽瀛(上海)生物技术有限公司 Wt1多肽肿瘤抑制剂
KR102476515B1 (ko) * 2020-09-11 2022-12-12 한국생명공학연구원 치주 질환 특이 항체 및 이의 용도
KR20220034563A (ko) * 2020-09-11 2022-03-18 한국생명공학연구원 신규 치주 질환 특이 항체 및 이의 용도
MX2024001843A (es) 2021-08-12 2024-05-16 Int Inst Cancer Immunology Inc Composición farmacéutica y método para tratar o prevenir cáncer.
EP4410304A4 (en) * 2021-09-24 2025-08-27 Cha Vaccine Res Institute Co Ltd CANCER VACCINE COMPOSITION COMPRISING PEPTIDES DERIVED FROM A TUMOR-ASSOCIATED ANTIGEN, AND AN ADJUVANT CONSISTING OF A LIPOPEPTIDE AND AN IMMUNOACTIVE SUBSTANCE, AND USE THEREOF

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3393867B2 (ja) * 1989-11-13 2003-04-07 マサチユーセツツ・インステイテユート・オブ・テクノロジー ウィルムス腫瘍遺伝子の位置決定と特徴付け
RU2100369C1 (ru) * 1992-04-22 1997-12-27 Варнер-Ламберт Компани Производные пептида или их фармацевтически приемлемые соли
US5705159A (en) * 1993-08-31 1998-01-06 John Wayne Cancer Institute Immunoreactive peptide sequence from a 43 KD human cancer antigen
US5622835A (en) * 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
WO1999058135A1 (en) * 1998-05-11 1999-11-18 The Salk Institute For Biological Studies Compositions for the treatment of tumors, and uses thereof
AU4932199A (en) * 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product

Also Published As

Publication number Publication date
ES2310052T3 (es) 2008-12-16
HK1039782B (en) 2008-11-14
CN100486995C (zh) 2009-05-13
KR100752065B1 (ko) 2007-08-28
JP2002525099A (ja) 2002-08-13
CA2349442A1 (en) 2000-04-06
MXPA01003344A (es) 2004-04-21
AR021849A1 (es) 2002-08-07
TR200101482T2 (tr) 2002-01-21
JP4235984B2 (ja) 2009-03-11
DE69938970D1 (de) 2008-08-07
IL142216A (en) 2009-06-15
CN1336935A (zh) 2002-02-20
MY139226A (en) 2009-08-28
WO2000018795A2 (en) 2000-04-06
PL348595A1 (en) 2002-06-03
ATE399179T1 (de) 2008-07-15
WO2000018795A3 (en) 2000-10-26
EP1117687A2 (en) 2001-07-25
SA00200872B1 (ar) 2007-01-30
HK1039782A1 (en) 2002-05-10
HUP0103598A2 (hu) 2002-01-28
JP2007001984A (ja) 2007-01-11
NO325839B1 (no) 2008-07-28
WO2000018795A9 (en) 2000-08-31
IL142216A0 (en) 2002-03-10
HUP0103598A3 (en) 2005-11-28
TW200606176A (en) 2006-02-16
NO20011613L (no) 2001-05-29
CA2349442C (en) 2012-12-04
TWI285648B (en) 2007-08-21
NO20011613D0 (no) 2001-03-29
RU2237674C2 (ru) 2004-10-10
BR9914116A (pt) 2002-01-15
JP2008069172A (ja) 2008-03-27
CZ20011144A3 (cs) 2002-06-12
KR20010085861A (ko) 2001-09-07
EP1117687B1 (en) 2008-06-25
JP4243792B2 (ja) 2009-03-25
NZ510600A (en) 2003-12-19
PL201881B1 (pl) 2009-05-29

Similar Documents

Publication Publication Date Title
CA2349442C (en) Compositions and methods for wt1 specific immunotherapy
US7063854B1 (en) Composition and methods for WTI specific immunotherapy
US7662386B2 (en) Compositions and methods for WT1 specific immunotherapy
AU2001296608B2 (en) Compositions and methods for WT1 specific immunotherapy
WO2001025273A2 (en) Compositions and methods for wt1 specific immunotherapy
US7144581B2 (en) Compositions and methods for WT1 specific immunotherapy
US20120301492A1 (en) Compositions and methods for wt1 specific immunotherapy
US7368119B2 (en) Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) Compositions and methods for WT1 specific immunotherapy
AU2003257511B2 (en) Compositions and methods for WT1 specific immunotherapy

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted